Ciência
Why pharma firms are betting billions on psychedelic drugs despite setbacks
Reprodução
Illustration: Adrià Voltà
The future of psychedelics is looking bright, after some dark times. Just two years ago, the US Food and Drug Administration (FDA) rejected an application to use MDMA — the active ingredient in the party drug ecstasy — to treat post-traumatic stress disorder. With that refusal, the whole field seemed to stall.
Por que isso importa?
Just two years ago, the US Food and Drug Administration (FDA) rejected an application to use MDMA — the active ingredient in the party drug ecstasy — to treat post-traumatic stress disorder.
Contexto Rápido
- Just two years ago, the US Food and Drug Administration (FDA) rejected an application to use MDMA — the active ingredient in the party drug ecstasy — to treat post-traumatic stress disorder.
- But now, billion-dollar investments and more clinical-trial data suggest that the field is forging ahead.
- Everyone can see that loud and clear.” In July, the drug giant Eli Lilly in Indianapolis, Indiana, announced plans to acquire AtaiBeckley, a psychedelic-medicine development firm in New York City, for up to US$3.8 billion.
Dados de contexto baseados em estatísticas públicas
e levantamentos históricos.
Fonte:
Nature-Notícias (Novo)
Comentários (0)
Entre para comentar nesta notícia.
Entrar com Google
Seja o primeiro a comentar.
Os comentários são de responsabilidade exclusiva de seus autores.
